PMEDAP and its N6-Substituted Derivatives: Genotoxic Effect and Apoptosis in in vitro Conditions

Anticancer Research

Volumn 23, Issue 6 C, 2003, Pages 4933-4939

  Valeriánová, Marie ^a   Otová, Berta ^a   Bílá, Vlasta ^a   Hanzalová, Jitka ^a   Votruba, Ivan ^b   Holý, Antonín ^b   Eckschlager, Tomáš ^c   Krejčí, Ondřej ^a   Trka, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Apoptosis; Genotoxicity; N6 substituted derivatives of PMEDAP

Indexed keywords

2,6 DIAMINOPURINE; 2,6 DIAMINOPURINE DERIVATIVE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2,6 DIAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] N6 (2 DIMETHYLAMINOETHYL) 2,6 DIAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] N6 ALLYL 2,6 DIAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] N6 CYCLOPROPYL 2,6 DIAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] N6 DIMETHYL 2,6 DIAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]GUANINE; UNCLASSIFIED DRUG; 2,6 DIAMINO 9 (2 PHOSPHONOMETHOXYETHYL)PURINE; 9-(2-PHOSPHONYLMETHOXYETHYL)-2,6-DIAMINOPURINE; ADENINE; DRUG DERIVATIVE;

ALLELE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHROMOSOME ABERRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG SENSITIVITY; EMBRYO DEATH; EMBRYOTOXICITY; FETOTOXICITY; FETUS DEVELOPMENT; GENOTOXICITY; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYDACTYLY; PRIORITY JOURNAL; TERATOGENICITY; TIME; CELL CULTURE; CELL DIVISION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; HUMAN CHROMOSOME; MITOSIS; MITOSIS INDEX; MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ADENINE; APOPTOSIS; CELL DIVISION; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; MITOSIS; MITOTIC INDEX; MUTAGENESIS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0842311654     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Holý A: Synthesis and biological activity of isopolar acyclic nucleotide analogs. In: Recent Advances in Nucleosides: Chemistry and Chemotherapy, Ed. by C. K. Chu, 167-238, Elsevier Science B.V., 2002.
2. Veselý J, Merta A, Votruba I, Rosenberg I and Holý A: The cytostatic effects and mechanism of action of antiviral acyclic adenine nucleotide analogs in L1210 mouse leukemia cells. Neoplasma 37: 105-110, 1990.
3. Rose WC, Crosswell AR, Bronson JJ and Martin JC: In vivo antitumour activity of 9-[(2-phosphonylmethoxy)ethyl]guanine and related phosphonate nucleotide analogues. J Natl Cancer Inst 82: 510-512, 1990.
4. Otová B, Zídek Z, Holý A, Votruba I, Sladká M, Marinov I and Lešková V: Antitumour activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP. In Vivo 11: 163-168, 1997.
5. Otová B, Zídek Z, Holý, A, Votruba I and Franková D: Immunomodulatory properties of 9-(2-phosphonomethoxyethyl) adenine (PMEA). Folia Biol (Praha) 40: 185-192, 1994.
6. Zídek Z, Holý, A, Franková D and Otová B: Suppression of rat adjuvant arthritis by some acyclic nucleotide analogs. Eur J Pharmacol 286: 307-310, 1995.
7. Bílá V, Otová B, Jelínek R, Sladká M, Mejsnarová B, Holý A and Křen V: Antimitotic and teratogenic effects of acyclic nucleotide analogues 1-(S)-(3-hydroxy-2-phosphonomethoxyethyl)cytosine (HPMPC) and 9-(2-phosphonomethoxyethyl) adenine (PMEA). Folia Biol (Praha) 39: 150-161, 1993.
8. Merta A, Votruba I, Jindřich J, Holý, A, Cihlář T, Rosenberg I, Otmar M and Herve TY: Phosphorylation of 9-(2-phosphonomethoxyethyl)adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP(dAMP) kinase from L1210 cells. Biochem Pharmacol 44: 2067-2077, 1992.
9. Krejčová R, Horská K, Votruba I and Holý A: Interaction of guanine phosphonomethoxyalkyl derivatives with GMP kinase isoenzymes. Biochem Pharmacol 60: 1907-1913, 2003.
10. Kramata P, Votruba I, Otová B and Holý A: Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol 49: 1005-1011, 1996.
11. Cihlář T and Chen MS: Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases alpha, beta and gamma. Antivir Chem Chemother 8: 187-195, 1997.
12. Birkug G, Votruba I, Holý A and Otová B: PMEApp as a substrate toward replicative DNA polymerases α, δ, ε, and ε*. Biochem Pharmacol 58: 487-492, 1999.
13. Franěk F, Holý A, Votruba I and Eckschlager T: Acyclic nucleotide analogues suppress growth and induce apoptosis in human leukemia cell lines. Int J Oncology 14: 745-752, 1999.
14. Otová B, Francová K, Franěk F, Koutnik P, Votruba I, Holý A, Sladká M and Schramlová J: 9-[2-(Phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP) - a potential drug against hematological malignancies-induces apoptosis. Anticancer Res 19: 3173-3182, 1999.
15. Bobková K, Otová B, Marinov I, Mandys V, Panczak A, Votruba I and Holý A: Anticancer effect of PMEDAP-monitoring of apoptosis. Anticancer Res 20: 1041-1048, 2000.
16. Bobková K, Gut I, Mandys V, Holý A, Votruba I and Otová B: Antitumour activity of a combined treatment with PMEDAP and docetaxel in the Prague inbred Sprague-Dawley/Cub rat strain bearing T-cell lymphoma. Anticancer Res 21: 2725-2732, 2001.
17. Otová B, Sladká M, Damoiseaux J, Panczak A, Mandys V and Marinov I: Relevant animal model of human lymphoblastic leukaemia/lymphoma - spontaneous T-cell lymphomas in an inbred Sprague-Dawley rat strain (SD/Cub). Folia Biol (Praha) 48: 213-226, 2002.
18. 6-substituted PMEDAP derivatives against T-cell lymphoma. Anticancer Res 21: 2057-2064, 2001.
19. Otová B, Holý A, Votruba I, Sladká M, Bźlá V, Mejsnarová B and Lešková V: Genotoxicity of purine acyclic nucleotide analogs. Folia Biol (Praha) 43: 225-229, 1997.
20. Křen V: Genetics of the polydactyly-luxate syndrome in the Norway rat, Rattus norvegicus. Acta Univ Carol Med (Monography) 68: 1-104, 1975.
21. Bílá V, Kašpárek R, Kršiaková M, Křen V, Křenová D, Otová B, Panczak A and Sladká M: Inbred rat congenic strains of the Norway rat. Rat News Lett 9: 45-47, 1982.
22. 6-substituted adenines, 2,6-diaminopurines and related compounds. Collect Czech Chem Commun 66: 1545-1592, 2001.
23. Bílá V and Křen V: Teratogenicity testing based on the interaction with a mutant allele. Folia Biol (Praha) 38: 40-47, 1992.
24. Bílá V and Křen V: Evidence of teratogenicity of thalidomide using congenic and recombinant inbred rat strains. Folia Biol (Praha) 40: 161-171, 1994.
25. Skulachev VP: Programmed death phenomena: from organelle to organism. Ann NY Acad Sci 959: 214-237, 2002.